blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2797912

EP2797912 - AZETIDINE-SUBSTITUTED QUINOXALINE-TYPE PIPERIDINE COMPOUNDS AND USES THEREOF [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  31.03.2017
Database last updated on 02.07.2024
Most recent event   Tooltip12.10.2018Lapse of the patent in a contracting state
New state(s): AL		published on 14.11.2018  [2018/46]
Applicant(s)For all designated states
Purdue Pharma L.P.
One Stamford Forum 201 Tresser Boulevard
Stamford, CT 06901-3431 / US
[2016/13]
Former [2016/04]For all designated states
Purdue Pharma L.P.
One Stamford Forum 201 Tresser Boulevard
Stamford, CT 06901-3431 / US
For all designated states
SHIONOGI & CO., LTD.
1-8, Doshomachi 3-chome
Chuo-ku
Osaka 541-0045 / JP
Former [2014/45]For all designated states
Purdue Pharma LP
One Stamford Forum 201 Tresser Boulevard
Stamford, CT 06901-3431 / US
For all designated states
Shionogi & Co., Ltd.
1-8, Doshomachi 3-chome
Chuo-ku
Osaka-shi, Osaka 541-0045 / JP
Inventor(s)01 / TAFESSE, Laykea
8 Windward Way
Robbinsville, NJ 08690 / US
02 / TSUNO, Naoki
c/o Shionogi & Co., Ltd.
1-1, Futabacho 3-chome
Toyonaka-shi
Osaka 561-0825 / JP
03 / ZHOU, Xiaoming
22 Dogwood Drive
Plainsboro, NJ 08536 / US
 [2014/45]
Representative(s)Vos, Derk
Maiwald GmbH
Elisenhof
Elisenstraße 3
80335 München / DE
[N/P]
Former [2014/45]Vos, Derk
Maiwald Patentanwalts GmbH
Elisenhof
Elisenstraße 3
80335 München / DE
Application number, filing date12813964.930.11.2012
[2016/21]
WO2012IB02689
Priority number, dateUS201161565836P01.12.2011         Original published format: US 201161565836 P
[2014/45]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2013080036
Date:06.06.2013
Language:EN
[2013/23]
Type: A1 Application with search report 
No.:EP2797912
Date:05.11.2014
Language:EN
The application published by WIPO in one of the EPO official languages on 06.06.2013 takes the place of the publication of the European patent application.
[2014/45]
Type: B1 Patent specification 
No.:EP2797912
Date:25.05.2016
Language:EN
[2016/21]
Search report(s)International search report - published on:EP06.06.2013
ClassificationIPC:C07D401/14, A61K31/498, A61P25/04
[2014/45]
CPC:
C07D413/14 (EP,US); A61P1/10 (EP); A61P1/12 (EP);
A61P1/14 (EP); A61P11/06 (EP); A61P13/02 (EP);
A61P25/04 (EP); A61P25/08 (EP); A61P25/16 (EP);
A61P25/22 (EP); A61P25/24 (EP); A61P25/28 (EP);
A61P25/36 (EP); A61P3/04 (EP); A61P43/00 (EP);
A61P9/12 (EP); C07D401/14 (EP,US) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2014/45]
Extension statesBA06.06.2014
ME06.06.2014
TitleGerman:AZETIDIN-SUBSTITUIERTE QUINOXALIN-TYP PIPERIDIN-VERBINDUNGEN UND IHRE VERWENDUNGEN[2016/03]
English:AZETIDINE-SUBSTITUTED QUINOXALINE-TYPE PIPERIDINE COMPOUNDS AND USES THEREOF[2014/45]
French:COMPOSÉS PIPÉRIDINE DE TYPE QUINOXALINE SUBSTITUÉS PAR AZÉTIDINE ET LEUR UTILISATION[2016/03]
Former [2014/45]AZETIDINSUBSTITUIERTE QUINOXALIN-PIPERIDINVERBINDUNGEN UND VERWENDUNGEN DAVON
Former [2014/45]COMPOSÉS DE PIPÉRIDINE DE TYPE QUINOXALINE SUBSTITUÉE PAR UNE AZÉTIDINE ET LEURS UTILISATIONS
Entry into regional phase06.06.2014National basic fee paid 
06.06.2014Designation fee(s) paid 
06.06.2014Examination fee paid 
Examination procedure06.06.2014Amendment by applicant (claims and/or description)
06.06.2014Examination requested  [2014/45]
11.08.2015Despatch of a communication from the examining division (Time limit: M04)
10.12.2015Reply to a communication from the examining division
07.01.2016Communication of intention to grant the patent
06.04.2016Fee for grant paid
06.04.2016Fee for publishing/printing paid
06.04.2016Receipt of the translation of the claim(s)
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  11.08.2015
Opposition(s)28.02.2017No opposition filed within time limit [2017/18]
Fees paidRenewal fee
07.11.2014Renewal fee patent year 03
06.11.2015Renewal fee patent year 04
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU30.11.2012
AL25.05.2016
AT25.05.2016
BE25.05.2016
BG25.05.2016
CY25.05.2016
CZ25.05.2016
DK25.05.2016
EE25.05.2016
FI25.05.2016
HR25.05.2016
IS25.05.2016
LT25.05.2016
LV25.05.2016
MC25.05.2016
MK25.05.2016
NL25.05.2016
PL25.05.2016
RO25.05.2016
RS25.05.2016
SE25.05.2016
SI25.05.2016
SK25.05.2016
SM25.05.2016
TR25.05.2016
NO25.08.2016
GR26.08.2016
PT26.09.2016
CH30.11.2016
IE30.11.2016
LI30.11.2016
LU30.11.2016
MT30.11.2016
[2018/46]
Former [2018/45]HU30.11.2012
AT25.05.2016
BE25.05.2016
BG25.05.2016
CY25.05.2016
CZ25.05.2016
DK25.05.2016
EE25.05.2016
FI25.05.2016
HR25.05.2016
IS25.05.2016
LT25.05.2016
LV25.05.2016
MC25.05.2016
MK25.05.2016
NL25.05.2016
PL25.05.2016
RO25.05.2016
RS25.05.2016
SE25.05.2016
SI25.05.2016
SK25.05.2016
SM25.05.2016
TR25.05.2016
NO25.08.2016
GR26.08.2016
PT26.09.2016
CH30.11.2016
IE30.11.2016
LI30.11.2016
LU30.11.2016
MT30.11.2016
Former [2018/43]HU30.11.2012
AT25.05.2016
BE25.05.2016
BG25.05.2016
CY25.05.2016
CZ25.05.2016
DK25.05.2016
EE25.05.2016
FI25.05.2016
HR25.05.2016
IS25.05.2016
LT25.05.2016
LV25.05.2016
MC25.05.2016
MK25.05.2016
NL25.05.2016
PL25.05.2016
RO25.05.2016
RS25.05.2016
SE25.05.2016
SI25.05.2016
SK25.05.2016
SM25.05.2016
NO25.08.2016
GR26.08.2016
PT26.09.2016
CH30.11.2016
IE30.11.2016
LI30.11.2016
LU30.11.2016
MT30.11.2016
Former [2018/38]HU30.11.2012
AT25.05.2016
BE25.05.2016
BG25.05.2016
CY25.05.2016
CZ25.05.2016
DK25.05.2016
EE25.05.2016
FI25.05.2016
HR25.05.2016
IS25.05.2016
LT25.05.2016
LV25.05.2016
MC25.05.2016
MK25.05.2016
NL25.05.2016
PL25.05.2016
RO25.05.2016
RS25.05.2016
SE25.05.2016
SI25.05.2016
SK25.05.2016
SM25.05.2016
NO25.08.2016
GR26.08.2016
PT26.09.2016
CH30.11.2016
IE30.11.2016
LI30.11.2016
LU30.11.2016
Former [2018/30]HU30.11.2012
AT25.05.2016
BE25.05.2016
CY25.05.2016
CZ25.05.2016
DK25.05.2016
EE25.05.2016
FI25.05.2016
HR25.05.2016
IS25.05.2016
LT25.05.2016
LV25.05.2016
MC25.05.2016
MK25.05.2016
NL25.05.2016
PL25.05.2016
RO25.05.2016
RS25.05.2016
SE25.05.2016
SI25.05.2016
SK25.05.2016
SM25.05.2016
NO25.08.2016
GR26.08.2016
PT26.09.2016
CH30.11.2016
IE30.11.2016
LI30.11.2016
LU30.11.2016
Former [2017/51]AT25.05.2016
BE25.05.2016
CZ25.05.2016
DK25.05.2016
EE25.05.2016
FI25.05.2016
LT25.05.2016
LV25.05.2016
NL25.05.2016
PL25.05.2016
RO25.05.2016
RS25.05.2016
SE25.05.2016
SI25.05.2016
SK25.05.2016
SM25.05.2016
NO25.08.2016
GR26.08.2016
PT26.09.2016
CH30.11.2016
IE30.11.2016
LI30.11.2016
LU30.11.2016
Former [2017/43]AT25.05.2016
BE25.05.2016
CZ25.05.2016
DK25.05.2016
EE25.05.2016
FI25.05.2016
LT25.05.2016
LV25.05.2016
NL25.05.2016
PL25.05.2016
RO25.05.2016
RS25.05.2016
SE25.05.2016
SI25.05.2016
SK25.05.2016
SM25.05.2016
NO25.08.2016
GR26.08.2016
PT26.09.2016
CH30.11.2016
LI30.11.2016
LU30.11.2016
Former [2017/37]AT25.05.2016
BE25.05.2016
CZ25.05.2016
DK25.05.2016
EE25.05.2016
FI25.05.2016
LT25.05.2016
LV25.05.2016
NL25.05.2016
PL25.05.2016
RO25.05.2016
RS25.05.2016
SE25.05.2016
SI25.05.2016
SK25.05.2016
SM25.05.2016
NO25.08.2016
GR26.08.2016
PT26.09.2016
CH30.11.2016
LI30.11.2016
Former [2017/11]AT25.05.2016
BE25.05.2016
CZ25.05.2016
DK25.05.2016
EE25.05.2016
FI25.05.2016
LT25.05.2016
LV25.05.2016
NL25.05.2016
PL25.05.2016
RO25.05.2016
RS25.05.2016
SE25.05.2016
SK25.05.2016
SM25.05.2016
NO25.08.2016
GR26.08.2016
PT26.09.2016
Former [2017/10]BE25.05.2016
CZ25.05.2016
DK25.05.2016
EE25.05.2016
FI25.05.2016
LT25.05.2016
LV25.05.2016
NL25.05.2016
PL25.05.2016
RO25.05.2016
RS25.05.2016
SE25.05.2016
SK25.05.2016
NO25.08.2016
GR26.08.2016
PT26.09.2016
Former [2017/09]CZ25.05.2016
DK25.05.2016
EE25.05.2016
FI25.05.2016
LT25.05.2016
LV25.05.2016
NL25.05.2016
RO25.05.2016
RS25.05.2016
SE25.05.2016
NO25.08.2016
GR26.08.2016
PT26.09.2016
Former [2017/07]DK25.05.2016
FI25.05.2016
LT25.05.2016
LV25.05.2016
NL25.05.2016
RS25.05.2016
SE25.05.2016
NO25.08.2016
GR26.08.2016
PT26.09.2016
Former [2016/52]FI25.05.2016
LT25.05.2016
LV25.05.2016
NL25.05.2016
RS25.05.2016
SE25.05.2016
NO25.08.2016
GR26.08.2016
PT26.09.2016
Former [2016/51]FI25.05.2016
LT25.05.2016
LV25.05.2016
NL25.05.2016
RS25.05.2016
NO25.08.2016
GR26.08.2016
PT26.09.2016
Former [2016/50]FI25.05.2016
LT25.05.2016
LV25.05.2016
NL25.05.2016
RS25.05.2016
NO25.08.2016
Former [2016/49]FI25.05.2016
LT25.05.2016
NL25.05.2016
NO25.08.2016
Former [2016/46]LT25.05.2016
NO25.08.2016
Cited inInternational search[AD]WO2010010458  (PURDUE PHARMA LP [US], et al) [AD] 1-62 * example - * * page 119; tables 1,2 * * claims 1, 2, 7, 33-39, 43, 47, 48 *
by applicantWO9946260
 WO9950254
 WO0190102
 WO2005028451
 WO03062234
 US2005256000
 US7355045
 US6562319
 WO2005075459
 US6635653
 US2010022519
 US2010216726
 US5698155
 US3845770
 US3916899
 US3536809
 US3598123
 US4008719
 US5674533
 US5059595
 US5591767
 US5120548
 US5073543
 US5639476
 US5354556
 US5733566
 US6136839
 US2011178090
    - HENDERSON ET AL., "The orphan opioid receptor and its endogenous ligand - nociceptin/orphanin FQ", TRENDS PHARMACOL. SCI., (1997), vol. 18, no. 8, doi:doi:10.1016/S0165-6147(97)90645-3, pages 293 - 300, XP004085920

DOI:   http://dx.doi.org/10.1016/S0165-6147(97)90645-3
    - CAIRA ET AL., "Preparation and Crystal Characterization of a Polymorph, a Monohydrate, and an Ethyl Acetate Solvate of the Antifungal Fluconazole", J. PHARMACEUT. SCI., (2004), vol. 93, no. 3, doi:doi:10.1002/jps.10541, pages 601 - 611, XP002653534

DOI:   http://dx.doi.org/10.1002/jps.10541
    - VAN TONDER ET AL., "Preparation and Physicochemical Characterization of 5 Niclosamide Solvates and I Hemisolvate", AAPS PHARM. SCI. TECH., (2004), vol. 5, no. 1
    - BINGHAM ET AL., "Over one hundred solvates of sulfathiazole", CHEM. COMM., (2001), pages 603 - 604
    - "Drug and Enzyme Targeting, Part A", COLOWICK ET AL., Methods in Enzymology, ACADEMIC PRESS, (1985), vol. 112
    - "Design and Application of Prodrugs", BUNDGAARD, A Textbook of Drug Design and Development, HARWOOD ACADEMIC PUBLISHERS, (1991), pages 113 - 191
    - BUNDGAARD ET AL., "C) Means to Enhance Penetration (1) Prodrugs as a means to improve the delivery of peptide drugs", ADV. DRUG DELIVERY REVS., (1992), vol. 8, doi:doi:10.1016/0169-409X(92)90014-H, pages 1 - 38, XP023764110

DOI:   http://dx.doi.org/10.1016/0169-409X(92)90014-H
    - BUNDGAARD ET AL., "Glycolamide Esters as Biolabile Prodrugs of Carboxylic Acid Agents: Synthesis, Stability, Bioconversion, and Physicochemical Properties", J PHARMACEUT. SCI., (1988), vol. 77, no. 4, doi:doi:10.1002/jps.2600770402, pages 285 - 298, XP000944531

DOI:   http://dx.doi.org/10.1002/jps.2600770402
    - KAKEYA ET AL., "Studies on Prodrugs of Cephalosporins. I. Synthesis and Biological Properties of Glycyloxygenzoyloxymethyl and Glycylaminobenzoyloxymethyl Esters of 7?-[2-(2-Aminothiazol-4-yl)-(Z)-2-methoxyiminoacetamido]3-methyl-3-cephem-4-carboxylic Acid", CHEM. PHARM. BULL., (1984), vol. 32, pages 692 - 698
    - "The Preparation and Characterization of Tritiated Neurochemicals", FILER ET AL., Isotopes in the Physical and Biomedical Sciences, Vol. 1, Labeled Compounds (Part A, (1987), vol. 1, pages 155 - 192
    - "Pharmacodynamics: Mechanisms of Drug Action and the Relationship Between Drug Concentration and Effect", ROSS ET AL., Goodman & Gilman's The Pharmacological Basis of Therapeutics, MCGRAW-HILL, (2001), pages 31 - 43
    - TORTOLANI ET AL., "A Convenient Synthesis to N-Aryl-Substituted 4-Piperidones", ORG. LETT., (1999), vol. 1, pages 1261 - 1262
    - DUDASH ET AL., "Synthesis and evaluation of 3-anilino-quinoxalinones as glycogen phosphorylase inhibitors", BIOORG. MED. CHEM. LETT., (2005), vol. 15, no. 21, doi:doi:10.1016/j.bmcl.2005.07.021, pages 4790 - 4793, XP025313928

DOI:   http://dx.doi.org/10.1016/j.bmcl.2005.07.021
    - "Hydrogenation of Nitro Compounds", Hydrogenation Methods, ACADEMIC PRESS, (1985), pages 104 - 116
    - "The Zinin Reduction of Nitroarenes", ORG. REACTIONS, (1973), vol. 20, pages 455 - 481
    - "Thionyl Chloride", PIZEY, Synthetic Reagents, JOHN WILEY & SONS, (1974), vol. 1, pages 321 - 357
    - PERREGAARD ET AL., "Studies on Organophosphorus Compounds XVIII*. Oxidation of Tertiary Alicyclic Amines with Elemental Sulfur in Hexa-methylphosphoric Triamide (HMPA). Oxidative Rearrangements of Hexahy-Droazepines and Octahydroazocines to bis(3-Pyrrolyl)Polysulfides", BULL. SOC. CHIM. BELG., (1977), vol. 86, pages 679 - 691
    - BERDINI ET AL., "A Modified Palladium Catalyzed Reductive Amination Procedure", TETRAHEDRON, (2002), vol. 58, doi:doi:10.1016/S0040-4020(02)00530-6, pages 5669 - 5674, XP004369415

DOI:   http://dx.doi.org/10.1016/S0040-4020(02)00530-6
    - LEWIN ET AL., "Molecular Features Associated with Polyamine Modulation of NMDA Receptors", J. MED. CHEM., (1998), vol. 41, pages 988 - 995
    - GRUPP ET AL., "Protection against Hypoxia-reoxygenation in the Absence of Poly (ADP-ribose) Synthetase in Isolated Working Hearts", J MOL. CELL CARDIOL., (1999), vol. 31, pages 297 - 303
    - SHIMOHIGASHI ET AL., "Sensitivity of Opioid Receptor-like Receptor ORL I for Chemical Modification on Nociceptin, a Naturally Occurring Nociceptive Peptide", J. BIOL. CHEM., (1996), vol. 271, no. 39, pages 23642 - 23645
    - NARITA ET AL., "Identification of the G-protein Coupled ORL 1 Receptor in the Mouse Spinal Cord by [35S]-GTP?S Binding and Immunohistochemistry", BRIT. J PHARMACOL., (1999), vol. 128, pages 1300 - 1306
    - MILLIGAN, "Principles: Extending the Utility of [35S]GTP?S Binding Assays", TIPS, (2003), vol. 24, no. 2, doi:doi:10.1016/S0165-6147(02)00027-5, pages 87 - 90, XP004404399

DOI:   http://dx.doi.org/10.1016/S0165-6147(02)00027-5
    - LAZARENO, "Measurement of Agonist-stimulated [35S]GTP?S Binding to Cell Membranes", METHODS IN MOLECULAR BIOLOGY, (1999), vol. 106, pages 231 - 245
    - LANGER, "New Methods of Drug Delivery", SCIENCE, (1990), vol. 249, doi:doi:10.1126/science.2218494, pages 1527 - 1533, XP000169082

DOI:   http://dx.doi.org/10.1126/science.2218494
    - "Dental Applications", GOODSON, Medical Applications of Controlled Release, Vol. 2, Applications and Evaluation, CRC PRESS, (1984), vol. 2, pages 115 - 138
    - LANGER, SCIENCE, (1990), vol. 249, pages 1527 - 1533
    - SEFTON, "Implantable Pumps", CRC CRIT. REV. BIOMED ENG., (1987), vol. 14, no. 3, pages 201 - 240, XP009142739
    - BUCHWALD ET AL., "Long-term, Continuous Intravenous Heparin Administration by an Implantable Infusion Pump in Ambulatory Patients with Recurrent Venous Thrombosis", SURGERY, (1980), vol. 88, pages 507 - 516, XP009142781
    - SAUDEK ET AL., "A Preliminary Trial of the Programmable Implantable Medication System for Insulin Delivery", NEW ENGL. J MED., (1989), vol. 321, pages 574 - 579, XP009142740
    - "Drug Product Design and Performance", GOODSON; SMOLEN ET AL., Controlled Drug Bioavailability, JOHN WILEY & SONS, (1984), vol. 1
    - LANGER ET AL., "Chemical and Physical Structure of Polymers as Carriers for Controlled Release of Bioactive Agents: A Review", J. MACROMOL. SCI. REV. MACROMOL. CHEM., (1983), vol. C23, no. 1, pages 61 - 126
    - LEVY ET AL., "Inhibition of Calcification of Bioprosthetic Heart Valves by Local Controlled-Release Diphosphonate", SCIENCE, (1985), vol. 228, pages 190 - 192, XP009142736
    - DURING ET AL., "Controlled Release of Dopamine from a Polymeric Brain Implant: In Vivo Characterization", ANN. NEUROL., (1989), vol. 25, doi:doi:10.1002/ana.410250406, pages 351 - 356, XP009035936

DOI:   http://dx.doi.org/10.1002/ana.410250406
    - HOWARD ET AL., "Intracerebral drug delivery in rats with lesion-induced memory deficits", J NEUROSURG., (1989), vol. 71, doi:doi:10.3171/jns.1989.71.1.0105, pages 105 - 112, XP008091921

DOI:   http://dx.doi.org/10.3171/jns.1989.71.1.0105
    - "Preformulation", RADEBOUGH ET AL., Remington's Pharmaceutical Sciences., 19th Ed.,, MACK PUBLISHING, (1995), vol. 2, pages 1447 - 1676
    - KING, "Tablets, Capsules, and Pills", KING, OSOL,, Remington's Pharmaceutical Sciences., 16th Ed., MACK PUBLISHING, (1980), pages 1553 - 1593
    - "Analgesic-Antipyretic and Anti-inflammatory Agents and Drugs Employed in the Treatment of Gout", INSEL ET AL., Goodman & Gilman's The Pharmacological Basis of Therapeutics, MCGRAW-HILL, (1996), pages 617 - 657
    - "Analgesic, Antipyretic and Anti-Inflammatory Drugs", HANSON, Remingtoh: The Science and Practice of Pharmacy, MACK PUBLISHING, (1995), vol. II, pages 1196 - 1221
    - HANESSIAN ET AL., "Asymmetric Synthesis of L-Azetidine-2-Carboxylic Acid and 3-Substituted Congeners - Conformationally Constrained Analogs of Phenylalanine, Naphthylalanine, and Leucine", BIOORG. MED. CHEM. LETT., (1999), vol. 9, doi:doi:10.1016/S0960-894X(99)00218-8, pages 1437 - 1442, XP004164908

DOI:   http://dx.doi.org/10.1016/S0960-894X(99)00218-8
    - ENDERS ET AL., "Asymmetric Synthesis of Substituted Azetidine Type a- and (?-Amino Acids", SYNTHESIS, (2005), vol. 20, pages 3508 - 3516
    - BRANDI ET AL., "Novel Syntheses of Azetidines and Azetidinones", CHEM. REV., (2008), vol. 108, pages 3988 - 4035
    - D'AMOUR ET AL., "A Method for Determining Loss of Pain Sensation", J PHARMACOL. EXP. THER., (1941), vol. 72, pages 74 - 79
    - BARTHO ET AL., "Involvement of capsaicin-sensitive neurons in hyperalgesia and enhanced opioid antinociception in inflammation", NAUNYN-SCHMIEDEBERG'S ARCHIVES OFPHARMACOL., (1990), vol. 342, pages 666 - 670
    - SELTZER ET AL., "A Novel Behavioral Model of Neuropathic Pain Disorders Produced in Rats by Partial Sciatic Nerve Injury", PAIN, (1990), vol. 43, doi:doi:10.1016/0304-3959(90)91074-S, pages 205 - 218, XP024377631

DOI:   http://dx.doi.org/10.1016/0304-3959(90)91074-S
    - KIM, "An Experimental Model for Peripheral Neuropathy Produced by Segmental Spinal Nerve Ligation in the Rat", PAIN, (1992), vol. 50, no. 3, doi:doi:10.1016/0304-3959(92)90041-9, pages 355 - 363, XP024378108

DOI:   http://dx.doi.org/10.1016/0304-3959(92)90041-9
    - STEIN, "Unilateral Inflammation of the Hindpaw in Rats as a Model of Prolonged Noxious Stimulation: Alterations in Behavior and Nociceptive Thresholds", PHARMACOL. BIOCHEM. BEHAVIOR, (1988), vol. 31, pages 451 - 455
    - HARGREAVES ET AL., "A New and Sensitive Method for Measuring Thermal Nociception in Cutaneous Hyperalgesia", PAIN, (1988), vol. 32, no. 1, doi:doi:10.1016/0304-3959(88)90026-7, pages 77 - 88, XP024378083

DOI:   http://dx.doi.org/10.1016/0304-3959(88)90026-7
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.